{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:05:05Z","timestamp":1775570705029,"version":"3.50.1"},"reference-count":9,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal muscle weakness and creatine kinase elevation over a 4-month course. Her symptoms were preceded by a single dose of semaglutide. Her work-up revealed features consistent with necrotising myopathy with inflammatory infiltrate on biopsy, and she responded to immunosuppression with corticosteroids and intravenous immunoglobulin (IVIG). She gradually improved and successfully returned to her baseline functional status while off immunosuppression for several months and with continued avoidance of glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we describe the first reported case of IMNM probably associated with GLP-1 receptor agonist use, with apparent response to a short course of immunosuppression and IVIG.<\/jats:p>","DOI":"10.1136\/bcr-2025-269690","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:35:14Z","timestamp":1772721314000},"page":"e269690","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?"],"prefix":"10.1136","volume":"19","author":[{"given":"Brian","family":"Lam","sequence":"first","affiliation":[{"name":"UTHealth Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Tiniakou","sequence":"additional","affiliation":[{"name":"UTHealth Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7524-2547","authenticated-orcid":false,"given":"Xinhai Robert","family":"Zhang","sequence":"additional","affiliation":[{"name":"UTHealth Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[{"name":"UTHealth Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026030506350642000_19.3.e269690.1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26 Suppl 4","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026030506350642000_19.3.e269690.2","doi-asserted-by":"crossref","unstructured":"Sonavane K , Shirsat P , Agrawal G , et al . Rhabdomyolysis Associated with the Use of Tirzepatide. Eur J Case Rep Intern Med 2025;12. doi:10.12890\/2025_005392","DOI":"10.12890\/2025_005392"},{"key":"2026030506350642000_19.3.e269690.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"2026030506350642000_19.3.e269690.4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(25)00233-9","article-title":"Advances in the classification and management of idiopathic inflammatory myopathies","volume":"24","author":"Raaphorst","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026030506350642000_19.3.e269690.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156"},{"key":"2026030506350642000_19.3.e269690.6","doi-asserted-by":"crossref","unstructured":"Lim J , Rietveld A , De Bleecker JL , et al . Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm 2019;6. doi:10.1212\/NXI.0000000000000513","DOI":"10.1212\/NXI.0000000000000513"},{"key":"2026030506350642000_19.3.e269690.7","doi-asserted-by":"crossref","unstructured":"Adler B , Christopher-Stine L , Tiniakou E . Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy. BMJ Case Rep 2022;15. doi:10.1136\/bcr-2022-248880","DOI":"10.1136\/bcr-2022-248880"},{"key":"2026030506350642000_19.3.e269690.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03224.x"},{"key":"2026030506350642000_19.3.e269690.9","doi-asserted-by":"crossref","unstructured":"Ellezam B , Troyanov Y , Landon-Cardinal O . Clinical pearls and histopathological features help discriminate toxic rhabdomyolysis from immune-mediated necrotizing myopathy in statin-exposed patients. Neuromuscul Disord 2025;51. doi:10.1016\/j.nmd.2025.105386","DOI":"10.1016\/j.nmd.2025.105386"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:35:16Z","timestamp":1772721316000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bcr-2025-269690"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269690","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}